Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776897 | 0.85 | TBXAS1 (0.46) | TBXAS1GAASMN1; SMN2FDPSALOX15 | |
| SCHEMBL10716164 | 0.82 | TBXAS1 (0.41) | TBXAS1GAASMN1; SMN2FDPSALOX15 | |
| SCHEMBL6013791 | 0.81 | KDM4E (0.46) | TBXAS1GAASMN1; SMN2FDPSALOX15 | |
| Water SCHEMBL2827597 | 0.80 | TBXAS1 (0.42) | TBXAS1GAASMN1; SMN2FDPSALOX15 | |
| Hydrochloric Acid SCHEMBL28900907 | 0.80 | KDM4E (0.49) | TBXAS1GAASMN1; SMN2FDPSALOX15 | |
| SCHEMBL16540538 | 0.79 | GAA (0.43) | TBXAS1GAASMN1; SMN2FDPSALOX15 | |
| SCHEMBL7866877 | 0.79 | HSD17B10 (0.50) | TBXAS1GAASMN1; SMN2TAAR1ALDH1A1 | |
| SCHEMBL2648602 | 0.79 | — | — | |
| SCHEMBL17499836 | 0.78 | TBXAS1 (0.39) | TBXAS1GAASMN1; SMN2FDPSALOX15 | |
| SCHEMBL8519473 | 0.78 | TBXAS1 (0.50) | TBXAS1GAASMN1; SMN2FDPSALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220399-A1 | Penicillanic acid derivative compounds and methods of making | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-11-04 | — | — | US | claimed |
| US-20030216372-A1 | Inhibitors of serine and metallo-beta-lactamases | ALAMX L.L.C. | 2003-11-20 | — | — | US | claimed |
| WO-2003087105-A1 | INHIBITORS OF SERINE AND METALLO-ß-LACTAMASES | ALAMX, L.L.C. (US) | 2003-10-23 | — | — | WO | claimed |
| US-20020198180-A1 | Penicillanic acid derivative compounds and methods of making | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-12-26 | — | — | US | claimed |
| US-6436398-B2 | ADMINISTERING A BETA-LACTAM ANTIBIOTIC WITH A BETA-LACTAMASE INHIBITING COMPOUND SUCH AS BENZHYDRYL 2-BETA-(CHLOROACETOXY-METHYL)-6-((Z)-(TERT-BUTOXYCARBONYL)METHYLENE) PENICILLINATE TO TREAT BETA-LACTAM RESISTANT BACTERIAL INFECTIONS | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-08-20 | — | — | US | claimed |
| EP-0966471-B1 | 2-BETA-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS BETA-LACTAMASE INHIBITORS | RES CORP TECHNOLOGIES INC (US) | 2002-06-12 | — | — | EP | claimed |
| US-20010021706-A1 | 2 beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2001-09-13 | — | — | US | claimed |
| US-6156745-A | 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-12-05 | — | — | US | claimed |
| EP-0966471-A1 | 2-BETA-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS BETA-LACTAMASE INHIBITORS | Research Corporation Technologies, Inc (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999033838-A1 | 2-β-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS β-LACTAMASE INHIBITORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | claimed |
| US-7125986-B2 | Penicillanic acid derivative compounds and methods of making | SOUTHERN METHODIST UNIVERSITY FOUNDATION FOR RESEARCH (US) | 2006-10-24 | — | — | US | disclosed |
| US-7022691-B2 | Inhibitors of serine and metallo-β-lactamases | Buynak, John D. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040220399-A1 | Penicillanic acid derivative compounds and methods of making | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-11-04 | — | — | US | disclosed |
| US-6770759-B2 | CEPHALOSPORINS FOR TREATING A BETA -LACTAM RESISTANT BACTERIAL INFECTION IN A MAMMAL; ENZYME INHIBITORS | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030216372-A1 | Inhibitors of serine and metallo-beta-lactamases | ALAMX L.L.C. | 2003-11-20 | — | — | US | disclosed |
| EP-0966471-B1 | 2-BETA-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS BETA-LACTAMASE INHIBITORS | RES CORP TECHNOLOGIES INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20010021706-A1 | 2 beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2001-09-13 | — | — | US | disclosed |
| US-6156745-A | 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0966471-A1 | 2-BETA-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS BETA-LACTAMASE INHIBITORS | Research Corporation Technologies, Inc (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999033838-A1 | 2-β-SUBSTITUTED-6-ALKYLIDENE PENICILLANIC ACID DERIVATIVES AS β-LACTAMASE INHIBITORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220399-A1 | Penicillanic acid derivative compounds and methods of making | MRPL21, CYP51A1, RPIA | TBXAS1 2637/4885GAA 135/4885SMN1; SMN2 1461/4885 |
| US-20020198180-A1 | Penicillanic acid derivative compounds and methods of making | MRPL21, RPIA, RPN1 | TBXAS1 2858/4885GAA 206/4885SMN1; SMN2 1303/4885 |
| US-20030216372-A1 | Inhibitors of serine and metallo-beta-lactamases | SRR, BACE1, PRSS1 | TBXAS1 2204/4885GAA 93/4885SMN1; SMN2 503/4885 |
| US-20010021706-A1 | 2 beta-substituted-6-alkylidene penicillanic acid derivatives as beta-lactamase inhibitors | IDUA, NAALAD2, GLA | TBXAS1 2794/4885GAA 36/4885SMN1; SMN2 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.